Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sqz Biotechnologies Company (NY:SQZ)

N/A UNCHANGED
Last Price Updated: 5:00 PM EDT, Jul 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sqz Biotechnologies Company

< Previous 1 2 3 Next >
News headline image
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
From GENENTA SCIENCE SPA
Via GlobeNewswire
News headline image
SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies Company
Via Business Wire
News headline image
NYSE:SQZ Investor Alert: Investigation over Potential Wrongdoing at SQZ Biotechnologies Company ↗
San Diego, CA -- (SBWIRE) -- 02/27/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at SQZ Biotechnologies Company. 
Via SBWire
News headline image
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
From SQZ Biotechnologies
Via Business Wire
News headline image
NYSE:SQZ Investor Notice: Investigation over Possible Securities Laws Violations by SQZ Biotechnologies Company ↗
San Diego, CA -- (SBWIRE) -- 12/13/2022 -- SQZ Biotechnologies Company is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
News headline image
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies to Present at Upcoming Investor Conferences
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies Announces Leadership Transition
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies to Present at Jefferies Healthcare Conference
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies to Present at Upcoming Investor Conferences
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo
From SQZ Biotechnologies
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.